Literature DB >> 21191484

Mean cancer mortality rates in low versus high elevation counties in Texas.

John Hart1.   

Abstract

There is controversy as to whether low levels of radiation (i.e., < 5 rem) pose a health risk. This brief inquiry compares archived cancer mortality data in counties having relatively low (0-250 feet above sea level), medium (500-1000 feet above sea level), and high (3000+ feet above sea level) elevations also having corresponding greater natural background levels of radiation respectively. Cancer mortality was found to be lowest in the high elevation counties (mean = 58.2) followed by low elevation counties (67.5) and then medium elevation counties (70.4). Statistically significant differences were found between low -high elevations (p = 0.003), and medium - high elevations (p = 0.010), but not between low and medium elevations (p = 0.5). More rigorous research, with an accounting of confounding variables, is indicated.

Entities:  

Keywords:  Radiation effects; Texas; background radiation; cancer; mortality

Year:  2010        PMID: 21191484      PMCID: PMC2990063          DOI: 10.2203/dose-response.09-047.Hart

Source DB:  PubMed          Journal:  Dose Response        ISSN: 1559-3258            Impact factor:   2.658


  7 in total

Review 1.  Descriptive studies: what they can and cannot do.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2002-01-12       Impact factor: 79.321

2.  Evidence for radiation hormesis after in vitro exposure of human lymphocytes to low doses of ionizing radiation.

Authors:  Kanokporn Noy Rithidech; Bobby R Scott
Journal:  Dose Response       Date:  2008-05-21       Impact factor: 2.658

3.  Natural background radiation and cancer death in Rocky Mountain states and Gulf Coast states.

Authors:  J Jagger
Journal:  Health Phys       Date:  1998-10       Impact factor: 1.316

4.  Test of the linear-no threshold theory of radiation carcinogenesis for inhaled radon decay products.

Authors:  B L Cohen
Journal:  Health Phys       Date:  1995-02       Impact factor: 1.316

Review 5.  Human exposure to high natural background radiation: what can it teach us about radiation risks?

Authors:  Jolyon H Hendry; Steven L Simon; Andrzej Wojcik; Mehdi Sohrabi; Werner Burkart; Elisabeth Cardis; Dominique Laurier; Margot Tirmarche; Isamu Hayata
Journal:  J Radiol Prot       Date:  2009-05-19       Impact factor: 1.394

6.  Natural background radiation and cancer mortality in the Republic of Ireland.

Authors:  S P Allwright; P A Colgan; I R McAulay; E Mullins
Journal:  Int J Epidemiol       Date:  1983-12       Impact factor: 7.196

7.  Radiation hormesis: the good, the bad, and the ugly.

Authors:  T D Luckey
Journal:  Dose Response       Date:  2006-09-27       Impact factor: 2.658

  7 in total
  5 in total

1.  The cancer mortality in high natural radiation areas in poland.

Authors:  Krzysztof Wojciech Fornalski; Ludwik Dobrzyński
Journal:  Dose Response       Date:  2012-01-12       Impact factor: 2.658

2.  Land elevation and cancer mortality in u.s. Cities and counties using median elevations derived from geographic information systems.

Authors:  John Hart
Journal:  Dose Response       Date:  2011-10-25       Impact factor: 2.658

3.  Radiation-hormesis phenotypes, the related mechanisms and implications for disease prevention and therapy.

Authors:  Bobby R Scott
Journal:  J Cell Commun Signal       Date:  2014-10-17       Impact factor: 5.782

4.  Utilization of artificial intelligence approach for prediction of DLP values for abdominal CT scans: A high accuracy estimation for risk assessment.

Authors:  H O Tekin; Faisal Almisned; T T Erguzel; Mohamed M Abuzaid; W Elshami; Antoaneta Ene; Shams A M Issa; Hesham M H Zakaly
Journal:  Front Public Health       Date:  2022-07-28

5.  Cancer Mortality Among People Living in Areas With Various Levels of Natural Background Radiation.

Authors:  Ludwik Dobrzyński; Krzysztof W Fornalski; Ludwig E Feinendegen
Journal:  Dose Response       Date:  2015-07-02       Impact factor: 2.658

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.